A practical reference on cyclic heptapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-06 and is reviewed periodically as new material appears.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
| Molecular mass | About 1024.2 g/mol | Monoisotopic value for the free base |
| Appearance | White to off-white lyophilized powder | Visual inspection is not an identity test |
| Solubility | Soluble in water and polar organic solvents | Dissolution depends on salt form and pH |
| Typical storage | -20 °C, dry, protected from light | Powder is more stable than prepared solutions |
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
The Treuhandanstalt (German: [ˈtʁɔɪ̯hantˌʔanʃtalt] , "Trust agency"), colloquially referred to as Treuhand, was a government agency of the German Democratic Republic (East Germany) from June to October 1990 and reunified Germany from 1990 to 1994, responsible for the reprivatisation/privatisation of the Volkseigene Betriebe (VEBs) and other state-owned enterprises in East Germany. The Treuhand was established by the Volkskammer of East Germany during Die Wende, to oversee the restructure and sale of about 8,500 state-owned companies with over four million employees – the world's largest industrial enterprise, controlling everything from steel works to the Babelsberg Studios. It inherited the assets of the Socialist Unity Party of Germany and other East German government agencies after German reunification in October 1990. The Treuhand was dissolved by the Federal Government of Germany on 1 January 1995 and reconstituted as the Federal Agency for Special Tasks Related to Unification (Bundesanstalt für vereinigungsbedingte Sonderaufgaben) which was active until 2000. The Treuhand has faced criticism and opposition for its handling of the privatisation process in the former East Germany, particularly for excessive liquidation and the resulting layoffs. On 1 April 1991, Treuhand chairman Detlev Karsten Rohwedder was assassinated by the Red Army Faction (RAF), a West German far-left terrorist group sponsored and supported by the East German Stasi. The shooter has never been identified.
Miyabi Sanekazura (真葛美 夜日, Sanekazura Miyabi) Head maid of the Town of Autumn Domestic Affairs Department. She is Nadeshiko's maid and works at the village's main shrine. She is strong-willed, caring, and skilled at her job. She can't help but love Nadeshiko and is happy to have been chosen as her head maid. Her family situation is a bit complicated. Koyoi Shirahagi (白萩 今宵, Shirahagi Koyoi) Member of the Town of Autumn's security. He is one of Rindo's closest subordinates and associates. He is a quiet, simple, and kind boy who takes care of Nadeshiko, but the little girl's guard dog does not seem to appreciate him and he often ends up being the victim of its pranks.
Day of Defeat received "generally favorable reviews" according to the review aggregation website Metacritic. IGN praised the game for its use of narrow spaces to stimulate the game's "relentless pacing", and GameSpy spoke highly of its attention to detail. Reviewers also praised Day of Defeat for its promotion of teamwork through purposefully tight corridors that force players to cooperate, lest they be killed by an enemy outside their field of vision. Both GameSpy and GameSpot levied criticism against the game for its sub-par visuals and "downright ugly" color palette, blaming the aging GoldSrc engine for the aesthetic issues. Many reviewers drew parallels between Day of Defeat and Battlefield 1942, the latter of which had been released only six months prior to the former. Both games were set in World War II and featured gameplay that was heavily reliant on their respective class-based systems, which lead reviewers to make direct comparisons between the two in their reviews of Day of Defeat. The game was also faulted for its lack of usable vehicles, contrasting Battlefield's usage of operable vehicles as a key gameplay component. PC Gamer US awarded Day of Defeat its 2001 "Mod of the Year" prize. The editors wrote, "Made by amateur developers not yet of American drinking age, Day of Defeat absorbed entire weeks of office LAN play."
Sources: en.wikipedia.org
=== Infection control concerns === Studies have shown that doctor's coats worn in hospitals can harbor contagions including MRSA. In 2007, the UK National Health Service (NHS) started banning long-sleeved coats. In 2009, the American Medical Association investigated banning coats with long sleeves to protect patients, but did not institute a ban. A study published in 2011 investigating the effectiveness of the NHS ban showed no statistical difference in contamination levels over an 8-hour period between residents wearing long-sleeved coats and those wearing short-sleeved scrubs. In an effort to reduce the contamination of healthcare uniforms, ASTM International is developing standards to specifically address liquid penetration resistance, liquid repellency, bacterial decontamination, and antimicrobial properties of such uniforms. The spread of white coat infection has been rampant and talked about in the scientific community. Indian physician Edmond Fernandes triggered a controversy in India and parts of South Asia by calling for a ban on white coats because of the spread of nosocomial infections.
=== Interactions between biomolecules === Coimmunoprecipitation Electrophoretic mobility shift assay Southwestern blotting Isothermal titration calorimetry Fluorescence anisotropy Microscale thermophoresis
=== Legal status === In September 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Mycapssa, intended for the treatment of adults with acromegaly. The applicant for this medicinal product is Amryt Pharmaceuticals DAC. Mycapssa was approved for medical use in the European Union in December 2022. In April 2025, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Oczyesa, intended for the maintenance treatment of adults with acromegaly. The applicant for this medicinal product is Camurus AB. Oczyesa is a hybrid medicine of Sandostatin, which has been authorized in the EU since November 1988. Oczyesa contains the same active substance as Sandostatin but as a different salt and is available at a higher strength and in a different pharmaceutical form. Oczyesa was authorized for medical use in the European Union in June 2025.
Evaporation and sublimation into a vacuum is called outgassing. All materials, solid or liquid, have a small vapour pressure, and their outgassing becomes important when the vacuum pressure falls below this vapour pressure. Outgassing has the same effect as a leak and will limit the achievable vacuum. Outgassing products may condense on nearby colder surfaces, which can be troublesome if they obscure optical instruments or react with other materials. This is of great concern to space missions, where an obscured telescope or solar cell can ruin an expensive mission. The most prevalent outgassing product in vacuum systems is water absorbed by chamber materials. It can be reduced by desiccating or baking the chamber, and removing absorbent materials. Outgassed water can condense in the oil of rotary vane pumps and reduce their net speed drastically if gas ballasting is not used. High vacuum systems must be clean and free of organic matter to minimize outgassing. Ultra-high vacuum systems are usually baked, preferably under vacuum, to temporarily raise the vapour pressure of all outgassing materials and boil them off. Once the bulk of the outgassing materials are boiled off and evacuated, the system may be cooled to lower vapour pressures and minimize residual outgassing during actual operation. Some systems are cooled well below room temperature by liquid nitrogen to shut down residual outgassing and simultaneously cryopump the system.
Sources: en.wikipedia.org
Dry powder is usually held frozen, shielded from light, and kept away from moisture. Desiccant packaging limits hydrolysis during storage. Solutions are typically aliquoted and frozen once, because repeated thawing shortens useful life.
Mass spectrometry establishes molecular mass, and reversed-phase chromatography reports purity. Peptide mapping or amino acid analysis supports sequence-level confirmation. No single technique covers all failure modes, so laboratories combine results.
Common entries include appearance, purity by chromatographic area, measured mass, and sometimes residual solvents or counter-ion content. Methods and instrument conditions are not always described. The document reflects the supplier's own testing unless an independent laboratory is named.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.